Converge Bio develops generative AI computational labs and virtual cell simulation applications engineered to optimize antibody design, gene expression, and biological target selection. The company is led by CEO Dov Gertz, CSO Dr. Iddo Weiner, and CTO Oded Kalev and is based in Boston, Massachusetts. Converge has advanced two independent drug programs through Phase 2 clinical trials and holds a licensed CRISPR discovery patent associated with Nobel laureate Jennifer Doudna. It has also established a 37-month cross-industry research partnership. With the $2.5 million Gates Foundation grant, Converge plans to expand its drug modeling platform into crop genomics, build multimodal long-context DNA foundation models, and accelerate breeding timelines for climate-resilient plants.

Total raised

$33M

Funding rounds

3

Latest round

Grant

Latest activity

Jun 2026